SCHEMBL3479528

SCHEMBL3479528

CN1CCN(c2ccc3ccccc3c2)c2ccc(-n3cccn3)cc2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.45
HRH3 Q9Y5N1 1/20 0.38
SCN9A Q15858 1/20 0.38
HRH4 Q9H3N8 1/20 0.36
CYP17A1 P05093 1/20 0.35
HTR6 P50406 3/20 0.35
HTR1A P08908 2/20 0.35
HTR2A P28223 2/20 0.35
HTR7 P34969 2/20 0.35
DRD2 P14416 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
AVPR2 P30518 1/20 0.34
F10 P00742 1/20 0.34
NPC1 O15118 1/20 0.34
MAPK1 P28482 1/20 0.34
NLRP3 Q96P20 2/20 0.34
CRHR1 P34998 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479666 0.89 DRD2 (0.40) SCN9AHTR1AHTR2AHTR7DRD2
SCHEMBL3235491 0.85 SCN9A (0.41) SCN9AHTR2ACCNA2CDK2CDK5
SCHEMBL3479720 0.84 CCNA2 (0.38) SCN9ACCNA2CDK2CDK5CDK5R1
SCHEMBL3236117 0.84 NOTUM (0.50) SCN9ADRD2AVPR2F10CRHR1
SCHEMBL3479595 0.83 HTR3A (0.44) HTR3ASCN9AHRH4CYP17A1HTR6
SCHEMBL3479774 0.83 SCN9A (0.38) SCN9AHTR2ACCNA2CDK2CDK5
SCHEMBL3479649 0.82 HRH3 (0.47) HTR3AHRH3SCN9ACYP17A1HTR6
SCHEMBL3227692 0.79 HTR3A (0.58) HTR3AHRH3NPC1
SCHEMBL3233131 0.79 HTR3A (0.51) HTR3AHRH3SCN9AHTR6HTR1A
SCHEMBL3227778 0.79 HTR3A (0.51) HTR3AHRH3SCN9AHTR6HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US claimed
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D HTR3A 30/4885HRH3 84/4885SCN9A 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.